FRM
DFTX

Fox Run Management’s Definium Therapeutics DFTX Stock Holding History

Fox Run Management’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$255K Sell
14,557
-16,151
-53% -$274K 0.04% 671
2025
Q4 		$411K Sell
30,708
-20,984
-41% -$260K 0.06% 579
2025
Q3 		$609K Buy
+51,692
New +$482K 0.1% 409

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fox Run Management's DFTX Position: Q1 2026 in Review

Fox Run Management reduced its Definium Therapeutics (DFTX) stake by 53% in Q1 2026, selling an estimated $274K and leaving 14,557 shares worth $255K. The position accounts for 0.04% of the portfolio, ranked #671.

Fox Run Management first reported a position in DFTX in Q3 2025 and has held it in 3 quarters since. The position peaked at $609K in Q3 2025. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

  • Fox Run Management held 14,557 shares of Definium Therapeutics worth $255K as of Q1 2026.
  • Fox Run Management sold 16,151 Definium Therapeutics shares in Q1 2026, an estimated $274K.
  • Definium Therapeutics made up 0.04% of Fox Run Management's portfolio in Q1 2026, its #671 holding.
  • Fox Run Management first reported a position in Definium Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Fox Run Management's Definium Therapeutics position peaked at $609K in Q3 2025.
  • 247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on Fox Run Management's 13F filing for Q1 2026, filed 12 May 2026.